Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 10, Issue 7, Pages 1201-1208Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.74
Keywords
Alzheimer's disease; antioxidants; oxidative stress; therapeutics
Categories
Funding
- Anavex
- Canopus BioPharma
- Medivation
- Neurotez
- Neuropharm
- Panacea Pharmaceuticals
- Voyager Pharmaceuticals
Ask authors/readers for more resources
Oxidative stress is an important factor, and one that acts in the earliest stages, of Alzheimer's disease (AD) pathogenesis. The reduction of oxidative stress has been tested as a therapy for AD. While the trial of vitamin E supplementation in moderately severe AD is the most promising so far, it also reveals the limitations of general antioxidant therapies that simply lower oxidative stress and, therefore, the complexity of the redox system. The multiple contributing factors that foster the clinical manifestations of AD should be considered when designing antioxidative stress therapy. In this article, we discuss the multiple pathogenic mechanisms of oxidative stress in AD and the potential targeting approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available